Skip to main content
. Author manuscript; available in PMC: 2020 Aug 14.
Published in final edited form as: Sci Transl Med. 2020 Mar 11;12(534):eaaw8275. doi: 10.1126/scitranslmed.aaw8275

Fig. 2. Increased percentage of MYCN-expressing cells in residual disease after neoadjuvant chemotherapy.

Fig. 2

(A) MYCN H-scores in residual disease from 115 primary, NAC-treated TNBCs (source: VUMC). Null, H-score=0. Int., intermediate, H-score >0 to ≤30. High, H-score >30. (B) Box plot showing MYCN H-scores in primary, treatment-naïve TNBC cases (n=191, see Fig. 1C) compared to residual disease from primary, NAC-treated TNBC cases (n=115, see Fig. 2A). Wilcoxon rank sum test, ***p=0.0001. (C) MYCN H-scores in patient-matched TNBC cases pre- and post-NAC (n=6, see table S2C for treatments and patient characteristics).